Cellect Biotechnology (NASDAQ:APOP) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a report issued on Friday, December 1st.
Separately, HC Wainwright reiterated a “buy” rating and set a $14.00 price target (up previously from $12.00) on shares of Cellect Biotechnology in a research note on Monday, September 25th.
Shares of Cellect Biotechnology (NASDAQ:APOP) traded down $0.04 during mid-day trading on Friday, reaching $7.49. 12,197 shares of the company were exchanged, compared to its average volume of 172,307. Cellect Biotechnology has a fifty-two week low of $2.30 and a fifty-two week high of $13.50.
A hedge fund recently bought a new stake in Cellect Biotechnology stock. Susquehanna International Group LLP purchased a new position in shares of Cellect Biotechnology Ltd. (NASDAQ:APOP) during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 12,764 shares of the company’s stock, valued at approximately $101,000. Susquehanna International Group LLP owned approximately 0.23% of Cellect Biotechnology as of its most recent SEC filing. 0.69% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This report was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.dispatchtribunal.com/2017/12/12/valuengine-downgrades-cellect-biotechnology-apop-to-sell.html.
About Cellect Biotechnology
Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cellect Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellect Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.